MEDICINE: Why a New Cancer Drug Works Well, In Some Patients

doi:10.1126/science.304.5671.658a

Account Information

Guest Alerts | Access Rights | My Account | Sign In

Site Navigation

Article Views

Article Tools

My Science

More Information

Related Jobs from ScienceCareers

Science 30 April 2004:
Vol. 304. no. 5671, pp. 658 - 659
DOI: 10.1126/science.304.5671.658a

Prev | Table of Contents | Next

News of the Week

MEDICINE:
Why a New Cancer Drug Works Well, In Some Patients

Jean Marx

A new drug called gefitinib (Iressa) has given cancer patients a glimmer of hope, while presenting a puzzle: Iressa causes significant tumor shrinkage in only about 10% of the patients who take it, but when it does work, clinicians say, it works amazingly well. Results published online by Science on 29 April provide an explanation for why Iressa is so much more effective in some patients than others.

Read the Full Text

The editors suggest the following Related Resources on Science sites:

In Science Magazine

REPORTS EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy: J. Guillermo Paez, Pasi A. Jänne, Jeffrey C. Lee, Sean Tracy, Heidi Greulich, Stacey Gabriel, Paula Herman, Frederic J. Kaye, Neal Lindeman, Titus J. Boggon, Katsuhiko Naoki, Hidefumi Sasaki, Yoshitaka Fujii, Michael J. Eck, William R. Sellers, Bruce E. Johnson, and Matthew Meyerson (4 June 2004)
Science 304 (5676), 1497. [DOI: 10.1126/science.1099314]
| Abstract » | Full Text » | PDF » | Supporting Online Material »

To Advertise | Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)

You have reached the bottom of the page. Back to top

Site Tools

Site Search

Account Information